New Delhi:Bharat Biotech on Friday said it has terminated agreements it had signed with two Brazilian companies - Precisa Medicamentos and Envixia Pharmaceuticals LLC to introduce its Covid-19 Covaxin in Brazil. In an official release, Bharat Biotech said "The said MoU was entered into with Precisa and Envixia for the purpose of introducing the company's innovative COVID-19 vaccine, COVAXIN in the territory of Brazil. The company has terminated the said MoU with immediate effect."
However, Bharat Biotech said it will continue to work diligently with ANVISA, the Brazilian drug regulatory body to complete the regulatory approval process for Covaxin. The company said it is pursuing approvals in various countries as per legal requirements applicable in each country. As part of its global supply outreach, the Hyderabad-based pharma firm has offered to supply Covaxin to Brazil.
Read: WHO assessing Covaxin data for EUL; Decision date "to be confirmed"